Selexipag shortage — BE supply status & alternatives

Selexipag

—

🇦🇺 AUST R 234161 · Janssen-Cilag Pty Ltd

In supply · Australia

Uptravi

In supply · 🇦🇺 Australia · short in🇮🇹 IT🇧🇪 BE

In supply in Australia

Reading today’s signals…

🇦🇺 AUAEMPA$3277.50details →

✓ Can I substitute?

In supply

no shortage substitution needed

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Active ingredient (INN)

Brand names	Uptravi

Therapeutic category	Auto-created by Agenzia Italiana del Farmaco — Carenze scraper

Controlled substance	No

Marketing-authorisation holders	Janssen-Cilag Pty Ltd, Zydus Pharmaceuticals (USA) Inc.

Registrations on file	17

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 PBS · July 2026

🇦🇺 AU

● Official price on file

Ex-manufacturer

A$3277.50

AEMP

Dispensed (DPMQ)

—

incl. fees

Pack

selexipag 400 microgram tablet, 60

Source: PBSEffective July 2026 · AUD

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

How long have past shortages lasted? from 1 resolved event

◷

~0 month

Historical pattern from resolved shortage records — not a prediction of this event.

Global API supply base 🇺🇸 FDA Drug Master Files · active Type II

8 API manufacturers

Manufacturers with an active Type II Drug Master File — i.e. cleared to supply this active ingredient into the US market. A proxy for how concentrated the global manufacturing base is.

Low concentration risk

Maithri Drugs Private LTDHonour Lab LTDApotex Pharmachem India PVT LTDBiophore India Pharmaceuticals PVT LTDAlembic Pharmaceuticals LTDZhejiang Huayi Pharmaceutical CO LTD+2 more

Manufacturing countries: India, China · Source: FDA List of Drug Master Files

FDA-approved products 🇺🇸 Drugs@FDA

Approved applications

Generic (ANDA)

Brand (NDA/BLA)

July 2021

Latest approval

Shortage status by regulator official notices

🇮🇹

Italy

AIFA · 4d ago

Medium

🇧🇪

FAMHP · 15d ago

Medium

Verified timeline regulator events

🇧🇪 8 June 2026

medium reported

🇮🇹 1 May 2026

medium reported

🇮🇹 20 Mar 2026

Shortage resolved

Sources official regulators

🇮🇹

AIFA

verified 4d ago

verify ↗

🇧🇪

FAMHP

verified 15d ago

verify ↗

Registration recordmarketing-authorisation holders

Registrations & marketing-authorisation holders17 registrations · 2 MA holders

Product	Strength	Form	Market	MA holder	Status
UPTRAVI selexipag	200 microgram	—	🇦🇺 AU	Janssen-Cilag Pty Ltd	Active
UPTRAVI selexipag	600 microgram	—	🇦🇺 AU	Janssen-Cilag Pty Ltd	Active
UPTRAVI selexipag	800 microgram	—	🇦🇺 AU	Janssen-Cilag Pty Ltd	Active
UPTRAVI selexipag	400 microgram	—	🇦🇺 AU	Janssen-Cilag Pty Ltd	Active
UPTRAVI selexipag	1000 microgram	—	🇦🇺 AU	Janssen-Cilag Pty Ltd	Active
UPTRAVI selexipag	1200 microgram	—	🇦🇺 AU	Janssen-Cilag Pty Ltd	Active
UPTRAVI selexipag	1400 microgram	—	🇦🇺 AU	Janssen-Cilag Pty Ltd	Active
UPTRAVI selexipag	1600 microgram	—	🇦🇺 AU	Janssen-Cilag Pty Ltd	Active
Selexipag	200ug/1	tablet	🇺🇸 US	Zydus Pharmaceuticals (USA) Inc.	Active
Selexipag	400ug/1	tablet	🇺🇸 US	Zydus Pharmaceuticals (USA) Inc.	Active
Selexipag	600ug/1	tablet	🇺🇸 US	Zydus Pharmaceuticals (USA) Inc.	Active
Selexipag	800ug/1	tablet	🇺🇸 US	Zydus Pharmaceuticals (USA) Inc.	Active
Selexipag	1000ug/1	tablet	🇺🇸 US	Zydus Pharmaceuticals (USA) Inc.	Active
Selexipag	1200ug/1	tablet	🇺🇸 US	Zydus Pharmaceuticals (USA) Inc.	Active
Selexipag	1400ug/1	tablet	🇺🇸 US	Zydus Pharmaceuticals (USA) Inc.	Active

+2 more registrations on file

Mederti Drug Report

Generated 6 July 2026 · Australia market · 2 regulatory sources

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.